68Ga-Pentixafor PET/CT for the Subtyping Diagnosis of Primary Aldosteronism: A Prospective Diagnostic Accuracy Study

  • STATUS
    Recruiting
  • End date
    Oct 10, 2023
  • participants needed
    100
  • sponsor
    Qifu Li
Updated on 10 May 2022

Summary

To evaluate the value of 68Ga-Pentixafor PET/CT in the diagnosis of primary aldosteronism subtype

Description

This is a prospective study. We will enroll 100 patients with definite diagnosis of PA using adrenal venous sampling(AVS) as the gold standard for subtype to evaluate the value of 68Ga-pentixaforPET/CT in the diagnosis of PA.

Details
Condition Primary Aldosteronism
Treatment Aldosterone/renin ratio(ARR) testing
Clinical Study IdentifierNCT05131061
SponsorQifu Li
Last Modified on10 May 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

diagnosed as PA
Voluntary to sign on the informed consent and willing to complete all follow-up
Have legal capacity and willingness to AVS and surgery

Exclusion Criteria

PA patients younger than 35 years old with typical APA characteristics (PAC > 200pg/ml, PRC < 2.5mIU/l, serum potassium < 3.5mmol/l, unilateral adenomatoid nodules larger than 1cm on CT)
AVS failure
AVS was successful, but PAC after correction of bilateral adrenal gland was lower than that of peripheral, and the typing was uncertain
Pregnant or lactate
Malignant tumor
intolerant to surgery, such as NYHA class 3 or 4, Severe anemia (Hb<60g/L)、stroke or acute coronary syndrome occurred within 3 months、end stage cirrhosis、eGFR<30ml/min/m2、untreated aneurysms, etc
PA with Cushing syndrome [including subclinical Cushing's syndrome, standard as: cortisol post-1mg DST > 140 or post-2mg DST> 50 (if the two results contradict, choose the 2mg DST result); if the cortisol post-1mgDST is between 50-140, add morning plasma ACTH < 10]
familial hyperaldosteronism
PA patients with pheochromocytoma or adrenocortical carcinoma on imaging
Alcoholics, drug addicts, and non-collaborators with mental disorders
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note